Key result
Xinshuitong Capsule reduced mortality and attenuated myocardial edema and cardiac remodeling in rats with Doxorubicin-induced chronic heart failure.
Why the study?
Although Xinshuitong Capsule has shown beneficial effects in chronic heart failure patients, its effect on doxorubicin-induced cardiotoxicity remains unclear.
Does Xinshuitong Capsule attenuate doxorubicin-induced cardiotoxicity and myocardial edema in a rat model of chronic heart failure?
RCT (n=90)
randomized
Does Xinshuitong Capsule attenuate doxorubicin-induced cardiotoxicity and myocardial edema in a rat model of chronic heart failure?
Answers are grounded in this paper and cite their sources.
Xinshuitong Capsule attenuates doxorubicin-induced cardiotoxicity, myocardial edema, and mortality in a rat model of chronic heart failure by inhibiting aquaporins 1, 4, and 7.
Doxorubicin (Dox), an effective antineoplastic drug, was limited use for cardiotoxicity. Xinshuitong Capsule (XST), a patented herbal formula, showed desirable beneficial effects in the treatment of chronic heart failure (CHF) patients. However, the drug on Dox-induced cardiotoxicity remains unclear. Ninety male Sprague-Dawley rats were randomized into two groups: 15 rats were selected as the normal group and 75 rats were injected intraperitoneally with Dox to establish CHF rat models, the success ones were randomly divided into five groups: low XST (LXST), medium XST (MXST) or high XST (HXST) (4.9, 9.8, or 19.6 g/kg d) administrated intragastrically twice a day for 4 weeks, with the captopril-treated group and the model group as comparison. The model group showed the cardiac functions generally impaired, and CHF mortality rate higher (47%) than those in the XST-treated groups (averaged 24%, P < 0.05). Compared with XST-treated groups, myocardial remodeling, inflammation and desarcomerization, and higher water content more severe in the cardiac tissue in the model group (P < 0.05), which was associated with higher expressions of mRNA or protein levels of AQP1, 4 and 7. Dox-impaired cardiac functions, cardiac remodeling and myocardial edema could be dose-dependently reverted by XST treatment. XST could inhibit AQP1, 4 and 7 at mRNA levels or at protein levels, which was associated with the attenuation of myocardial edema and cardiac remodeling, decreasing the ventricular stiffness and improving the cardiac functions and rats' survival. AQPs is involved in cardiac edema composed one of the mechanisms of Dox-induced cardiotoxicity, XSTvia inhibition of AQPs relieved the Dox-induced side effects.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2021) conducted an RCT in Doxorubicin-induced chronic heart failure (n=90). Xinshuitong Capsule (XST) vs. Model group (untreated) and captopril-treated group was evaluated on Mortality rate (p=< 0.05). Xinshuitong Capsule reduced mortality and attenuated myocardial edema and cardiac remodeling in rats with Doxorubicin-induced chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: